Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20

Objective To examine the differences in therapy response and confirm the effective regimen for multiple myeloma (MM) patients with t (11; 14)/CD20- or CD20+, for the selection of transplantation as early treatment. Methods To find the differences in therapy response and to confirm the effective regimen for multiple myeloma (MM) patients with t (11; 14)/CD20- or CD20+, for the selection of transplantation as the early treatment. There were three cytogenetics groups: t(11; 14)/CD20- or CD20+ and low-risk profile including normal or cytogenetics other than t (11; 14). Eligible patients received the bortezomib-based induction and lenalidomide-based consolidation/maintenance regimen. Results Patients with t(11;14) gained adverse therapy response for bortezomib induction regimen than other low-risk arm (OR rate: 11.1% versus 84.0% versus 85.2%, P＜0.01). A prospective found that although the patients with t(11;14)/CD20- showed the poor overall response for the bortezomib-based regimen, lenalidomide-based treatment s